Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Ist Teil von
The New England journal of medicine, 2005-03, Vol.352 (11), p.1071-1080
Ort / Verlag
Boston, MA: Massachusetts Medical Society
Erscheinungsjahr
2005
Link zum Volltext
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
Using data from a clinical trial of celecoxib to prevent colorectal adenomas, these investigators analyzed cardiovascular events over a three-year follow-up period. There was a dose-related increase in the risk of a composite outcome of death from cardiovascular causes, myocardial infarction, stroke, or heart failure. The hazard ratio was 2.3 with a 200-mg dose and 3.4 with a 400-mg dose. These results raise concern that the use of celecoxib is associated with a serious risk of cardiovascular events.
Using data from a clinical trial of celecoxib to prevent colorectal adenomas, these investigators found a dose-related increase in the risk of a composite outcome of death from cardiovascular causes, myocardial infarction, stroke, or heart failure.
The promise of a lower incidence of gastrointestinal side effects with the use of selective cyclooxygenase-2 (COX-2) inhibitors than with the use of nonselective nonsteroidal antiinflammatory drugs (NSAIDs) or aspirin has led to a marked increase in prescriptions for COX-2 inhibitors, despite the fact that they offer similar degrees of pain relief.
1
–
3
In addition, the identification of COX-2 as a promoter of intestinal tumorigenesis suggested that inhibiting this enzyme could prevent the formation of premalignant colorectal adenomas.
4
–
8
Recently, however, this class of drugs has come under scrutiny because of clinical reports that they were associated with an increased . . .